Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 7Neoplasm Metastasis 2Adenocarcinoma 2Pancreatic Ductal Adenocarcinoma (PDAC) 1Neoplasms 1Locally Advanced Unresectable or Metastatic Solid Tumors 1Gastroesophageal Adenocarcinoma 1Carcinoma 1

Interventions

Fluorouracil 11Gemcitabine 8pembrolizumab 7Leucovorin 7Irinotecan 7Paclitaxel 6Oxaliplatin 5Carboplatin 5130-nm albumin-bound paclitaxel 5Nivolumab 4Cisplatin 4Albumin-Bound Paclitaxel 4Taxes 3Ramucirumab 3Radiosurgery 3Pemetrexed 3Docetaxel 3Capecitabine 3Bevacizumab 3vandetanib 2spartalizumab 2selinexor 2osimertinib 2folfirinox 2Radiation 2Cyclophosphamide 2zolbetuximab 1trastuzumab deruxtecan 1trametinib 1tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Adenocarcinoma × folfirinox × Clear all
NCT04990037 2023-06-29

CAPAFOUR

Cantargia AB

Phase 1 Completed
25 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT01383538 2017-08-08

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

University of California, San Francisco

Phase 1 Completed
15 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡